ABSTRACT: Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which fall just within BCS Class IV. Aciclovir seems not to be critical with respect to a risk for bioinequivalence, as no examples of bioinequivalence have been identified. It has a wide therapeutic index and is not used for critical indications. Hence, if: (a) the test product contains only excipients present in aciclovir solid oral IR drug products approved in ICH or associated countries, for instance as presented in this article; and (b) the comparator and the test product both are very rapidly dissolving, a biowaiver for IR aciclovir solid oral drug products is considered justified for all tablet strengths. ß
INTRODUCTION
A biowaiver monograph of aciclovir based on literature data is presented. The risks of basing a BE assessment on in vitro rather than in vivo study results for the approval of new IR solid oral dosage forms containing aciclovir (''biowaiving''), including both reformulated products and new multisource products, are evaluated under consideration of its biopharmaceutical and clinical properties. This evaluation refers to drug products containing aciclovir as the only active pharmaceutical ingredient (API) and not to combination drug products.
The purpose and scope of this series of monographs have been previously discussed. 1 Summarized in few words, the aim is to evaluate all pertinent data available from literature sources for a given API to assess the risks associated with a biowaiver. For these purposes, risk is defined as the probability of an incorrect biowaiver decision as well as the consequences of the decision in terms of public health and individual patient risks. On the basis of these considerations, a recommendation can be made as to whether a biowaiver is advisable or not. This systematic approach to recommend or advise against a biowaiver decisions is referred to in the recently published World Health Organization (WHO) Guideline. 2 It is to be understood that these monographs do not simply apply the WHO, 2 FDA, 3 and EMEA Guidances, 4 but also aim to serve as a critical validation of these regulatory documents. Biowaiver monographs have already been published for acetaminophen (INN: paracetamol), 5 acetazolamide, 6 amitriptyline, 7 atenolol, 1 chloroquine, 8 cimetidine, 9 ethambutol, 10 ibuprofen, 11 isoniazid, 12 prednisolone, 13 prednisone, 14 pyranisamide, 15 propranolol, 1 ranitidine, 16 and verapamil. 1 They are also available on-line at www.fip.org/bcs.
EXPERIMENTAL
Literature data was assessed from PubMed 17 and Micromedex 18 databases. Keywords used for searching, in various combinations were: aciclovir, acyclovir, solubility, permeability, dissolution. Information was also obtained from regulatory documents published by the EMEA, 4 the FDA, 3 and the WHO. 2, 19 The USP 20 and the European Pharmacopoeia 21 were also consulted when necessary.
GENERAL CHARACTERISTICS Name
The INN and WHO chemical name for aciclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6H-purin-6-one, or 9-[(2-hydroxyethoxy)methyl]-guanine. 20, 22 Other names are: acyclovir, acycloguanosine and ACV. 23 Its molecular formula is C 8 H 11 N 5 O 3 , and its molecular weight is 225.21 g/mol. Its CAS number is 59277-89-3.
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Therapeutic Indications, Therapeutic Index and Toxicity Aciclovir is used orally for the treatment and prophylaxis of initial and recurrent episodes of genital and labial herpes and for the acute treatment of herpes zoster for the treatment of varicella (chickenpox) in immunocompetent individuals. 24, 25 Its defined daily dose, either orally or parenterally, is 4 g. 26 Oral administration up to doses of 4800 mg/day is usually well tolerated although high-dose treatment with oral aciclovir for herpes zoster results can cause more side effects than low-dose treatments. 27 Several patients have ingested up to 100 capsules, corresponding to 20 g of aciclovir, with no apparent adverse effects, 28 probably due to the limited solubility and absorption characteristics. Neurotoxicity may be seen with high doses in patients with compromised renal function. delirium, encephalopathy, hallucinations, paresthesias, psychosis, seizures, or tremor. Neurologic adverse reactions usually occur within 1-2 days of achieving the maximum aciclovir concentration and may not be directly correlated with the aciclovir serum concentrations at the time the toxic effects appear. The threshold for neurotoxicity was reported to be 4.5 mg/mL, whereas the normal peak range is 0.4-2 mg/mL. 28 Diarrhea, nausea and vomiting, and elevated serum creatinine levels may be observed in conjunction with plasma levels over 20 mcg/mL, but recede when the dose is reduced. 28 Serious neurological and/or psychiatric adverse effects been reported in a few patients administered bolus injections of high doses intravenous aciclovir. 27, 28, 30 Aciclovir has low solubility in urine and aciclovir crystals may precipitate in the renal tubules if the solubility is exceeded in the intratubular fluid, resulting in renal dysfunction, renal failure or anuria, 24, 28 but this crystalluria is most likely to occur only during administration of large, parenteral doses. All these latter adverse drug reactions are not associated with the oral administration and hence are not relevant for this monograph.
PHYSCOCHEMICAL PROPERTIES Salts, Esters, Polymorphs, Hydrates
Aciclovir is commonly used as the free acid form in solid oral dosage forms, whereas the sodium salt is used in parenteral dosage forms. 22, 23 Valaciclovir, the L-valyl ester of aciclovir, has been used orally to increase its BA. [31] [32] [33] [34] [35] [36] Several dipeptide ester prodrugs are being tested to assess their usefulness in therapeutics, 37, 38 as well as some bile acid conjugate prodrugs 39 and a phospholipid prodrug. 40 The scope of this monograph is restricted to drug products containing aciclovir as the free acid.
Aciclovir is normally present in a hydrated form consisting of three aciclovir molecules to two molecules of water, 41 corresponding to a theoretical water content of about 5%, but dose and solubility are normally expressed in units of anhydrous aciclovir. 20, 42 A stable anhydrous form can be obtained by drying hydrated aciclovir at temperatures above 1508C. 41 Although only slight and insignificant differences in solubility values exist between these two forms, the anhydrous form of aciclovir possesses poorer dissolution properties than the hydrated form. 41 
Solubility
Aciclovir is described as ''slightly soluble in water'' in different Pharmacopoeias. 20, 21 Most data found in literature are calculated at room temperature (22-258C), reporting solubility values that range from 1.2 to 1.6 mg/mL. 41, [43] [44] [45] [46] [47] In water at 378C, solubility has been reported to be 2.5 mg/mL. 24 A plot of the pH-solubility in de-ionized water at 378C was published, showing the solubility to vary slightly with pH, with a lowest solubility of 2.3 mg/ mL at pH 5.8 at 378C. 48 The solubility data in Table 1 were obtained from this pH-solubility profile.
Partition Coefficient
The partition coefficient (log P) in n-octanol at 228C is À1.57.
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At 258C, log P and log D were both reported to be À1. 8 44,50 at pH 6.8. Calculations by Kasim et al. using fragmentation methods based on atomic contributions to lipophilicity and by using the C log P 1 program (version 3.0, Biobyte Corp., Claremont, CA, http://www.biobyte.com) gave values of À2.42 for C log P 1 , and À1.59 for log P, respectively. 51 
pK a
Aciclovir is an ampholyte with both weak acid and basic groups. Common literature pK a values for aciclovir are 2.27 and 9.25, but it is not stated at which temperature they were measured. 23, 24 Balon et al. 50 reported pK a values of 2.16 and 9.04 at 378C. 
Dosage Form Strengths
The WHO Model List of Essential Medicines lists a dosage strength of 200 mg for aciclovir. 19 Most European countries have Marketing Authorizations (MAs) for IR solid oral dosage forms of 200 and 400 mg, but some countries also have an MA for a 800 mg strength, see Table 2 . The USA has MA's for IR solid oral dosage forms of 200, 400, and 800 mg. 52 
PHARMACOKINETIC PROPERTIES Permeability and Absorption
Data found in the literature for Caco-2 permeability are summarized in Table 3 .
A permeability study employing 3H-aciclovir indicated an apparent permeability coefficient of about 1.19 Â 10 À5 cm/s, 53 but other reports obtained considerably lower values, ranging from of 0.12 Â 10 À6 44 to 2.0 Â 10 À6 cm/s, 54 see Table 3 . As drugs with a permeability in the range 70-100% absorbed usually have a P app value greater than 10 Â 10 À6 cm/s, 54 most of these data suggest that permeability of aciclovir is low. It has also been hypothesized that a log P value greater than that of metoprolol (1.72) indicates high permeability. 51 As all log P values reported for aciclovir lie far below that value (see above), according to this paradigm aciclovir is expected to have low permeability.
Aciclovir's absolute BA following oral administration has been reported to be in a range of 10-30% in humans. 18, 22, 23, 25 This poor systemic BA is considered to be a result of the characteristics of the drug itself and not its delivery vehicle. 18, 25 Its absorption occurs mainly by passive diffusion mechanism and it is slow, variable and incomplete. 23, 55 Maximum plasma concentrations are reached within 1.5-2.5 h. 18, 22, 23, 55, 56 Aciclovir shows a two compartment pharmacokinetic behavior, regardless of the dosage, duration of treatment or frequency of administration. 36 After multiple dose administration, steady-state concentrations are reached in 1-2 days. 18 Some studies suggest that increasing doses result in decreasing BA 23, 25, 35 or less than proportional increases in C max 57 and it has been suggested that this behavior may be due to a saturable carrier system or a limited area for absorption in the gastro-intestinal (GI) tract or to the low solubility of this API. 18, 46, 55 Other studies found nearproportional increases in AUC with increasing doses in the dose range used clinically of 100-800 mg. 34, 47 Food does not appear to affect the rate and extent of absorption. 18, 23, 25, 55 Distribution Aciclovir is widely distributed into most body tissues, including the brain, kidney, lung, liver, heart tissue, muscle, spleen, placenta, uterus, vaginal mucosa and secretions, semen, saliva, amniotic fluid, aqueous humor and cerebrospinal fluid. 18, 23 Aciclovir demonstrates minimal protein binding (9-33%) at therapeutic plasma concentrations. 18, 23, 24 
Metabolism and Excretion
Most of a single aciclovir dose (62-91% of an intravenous dose) is excreted unchanged in urine via glomerular filtration and tubular secretion, in adults with normal renal function. 23, 24 Aciclovir is metabolized in the liver, partially to 9-(carboxymethoxy)methyl]guanine (CMMG) and minimally to 8-[(hydroxy-9-(2-hydroxiethoxy)methyl]-guanine. 18, 23, 24 The only known urinary metabolite is CMMG. Plasma concentrations of aciclovir appear to decline in a biphasic manner. In adults with normal renal function, t 1/2 a averages 0.34 h and t 1/2 b averages 2.1-3.5 h. 18, 23, 24, 55 
DOSAGE FORM PERFORMANCE Bioequivalence of Different Formulations
Six in vivo BE studies comparing drug products with the innovator drug product, Zovirax 1 , were identified. Details of these studies are presented in Table 4 . In all of them, the comparator and the generic formulations were bioequivalent. [58] [59] [60] [61] [62] Moreover, in some Summary of Products Characteristics (SmPCs) of drug products with a MA in DE, results of successful in vivo BE studies are reported. The SmPCs of Aciclovir-CT 200/400/ 800 mg Tabletten 63 reports in vivo BE studies of each of the three tablet strengths, while the SmPC of Virzin 200/400/800 mg 63 reports in vivo BE studies of the 400 and 800 mg strength. All these studies used 20 volunteers and BE was established according to AUC, C max , and T max. It is very likely that in all studies the reference product is Zovirax 1 , being the innovator on the DE market. 
Excipients
In the above-mentioned BE studies, various excipients were used in the formulations. Aciclovir-CT tabletten contain cellulose, crospovidone, magensium stearate, sodium starch glycolate, lactose (200 and 400 mg strengths only) and silica (800 mg strength only); 63 Virzin contains cellulose; magnesium stearate silica, sodium starch glycolate, starch (200 and 400 mg strengths only), crospovidone (800 mg strength only) and povidone (200 and 400 mg strengths only), 63 whereas Zovirax 1 contains aluminum magnesium silicate, cellulose, hypromellose, macrogol, magnesium stearate, povidone, and sodium starch glycolate; 63 see also Table 2 . A study carried out with Caco-2 showed that, of nine common excipients studied, only sodium lauryl sulfate slightly increased the permeability of aciclovir, whereas lactose, hydroxypropyl methyl cellulose, Tween 80, propylene glycol, polyethylene glycol 400, dioctyl sodium sulfosuccinate, sodium EDTA and anhydrous cherry flavor, had no effect on the permeability. 64 Excipients present in aciclovir IR solid oral drug products with a MA in Germany (DE), Denmark (DK), Finland (FI), France (FR), The Netherlands (NL), Norway (NO), Spain (ES) and Sweden (SE), are shown in Table 2 . Additionally, the minimum and maximum amount of the listed excipients present per dosage unit in solid oral drug products with a MA in the USA, taken from the FDA Inactive Ingredient Data Base, 65 is indicated. It can be expected that the drug products having a MA in the reported countries successfully passed an in vivo BE study. In DE, the exemption from demonstration of BE in vivo that existed for some APIs in the 1980s and 1990s was not applied to The upper range value reported is unusual high for solid oral dosage forms and the authors doubt on its correctness.
aciclovir. 66 Similarly, aciclovir is not on the list of APIs exempted from demonstration of BE in vivo for IR solid oral drug products seeking a national MA only in The Netherlands. 67 
Dissolution
The USP 29 dissolution specifications for Aciclovir Tablets are not less than 80% (Q) of the labeled amount dissolved within 45 min in 900 mL of 0.1 N hydrochloric acid, using the paddle at 50 rpm, and for Aciclovir Capsules the specification is not less than 75% (Q) within 45 min in 900 mL of 0.1 N hydrochloric acid, using the basket at 100 rpm, respectively. 20 The dissolution of the innovator and five generic drug products, each containing 800 mg aciclovir, was compared using USP apparatus 2 and USP apparatus 3. The dissolution of all drug products was complete within in 15 min, in both apparatus. 68 One of the six in vivo BE studies mentioned above compared the dissolution of innovator and generic drug products as stipulated by USP XXIII, finding them to be not statistically different. Table 1 . The WHO recommended dosage strength and the 400 mg strength qualify as highly soluble according to all Guidelines. [2] [3] [4] However, in some markets, the highest dosage strength is 800 mg, for which that criterion is not met.
Permeability
The BA for aciclovir ranges from 10% to 30%, indicating, given the small amount of metabolism, that this API is not highly permeable according to all Guidelines. [2] [3] [4] Caco-2 permeability data and log P oct values support that conclusion. 
BCS Classification
Combining the data on solubility and permeability, according to all Guidelines, 2-4 the 200 and 400 mg tablet strengths are BCS Class III. Kasim et al. 51 also classified aciclovir as BCS Class III, but their classification was based on correlations of partition coefficients with permeability, a method not supported by HHS-FDA and other regulatory authorities due to its limited predictability. Lindenberg et al. 69 and the recently adopted revised WHO Guideline 2 also classify aciclovir as BCS Class III. Wu and Benet, 70 using the disposition characteristics of the API as estimate for its permeability, assigned aciclovir to Class III of their Biopharmaceutics Drug Disposition Classification System (BDDCS). For pH values 4.5 and above, the 800 mg tablet strength shows D/S ratio's outside the 250 mL limit. If 800 mg is taken as highest tablet strength, aciclovir would be classified in BCS Class IV.
Surrogate Techniques for In Vivo Bioequivalence Testing
The low permeability of aciclovir is the limiting step in its absorption process. Bioinequivalence caused by differences in GI permeability between test and comparator, caused by an excipient effect, can only be circumvented by formulating the test product only with excipients known not to affect GI permeability. Bioinequivalence caused by differences in in vivo disintegration and/or in vivo dissolution between test and comparator, being a potential cause of bioinequivalence in particular for 800 mg tablet strengths, can be excluded by requiring the comparator and the test product to be both very rapidly dissolving, that is, dissolve 85% in 15 min or less, using a basket apparatus at 100 rpm or paddle apparatus at 50 rpm, in a volume of 900 mL or less, in the three BCS-media.
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Risks of Excipient and/or Manufacturing to Cause Bioinequivalence
One report was identified of an excipient interaction, being an in vitro study only, using Caco-2, with sodium laurylsulfate, and the effect was limited. 64 For the excipients shown in Table 2 , it can be supposed that they show no influence on the absorption of aciclovir when present in usual amounts; note that Table 2 does not include sodium laurylsulfate. From a more general perspective, aciclovir seems not to be a critical API with respect to a risk for bioinequivalence: not one single example of bioinequivalence was identified, whereas eight in vivo BE studies were identified demonstrating in vivo BE of different formulations. Furthermore, 87 drug products (with MAs) were identified, for which it can be assumed that an in vivo BE study was successfully passed, which contain a wide variety of compositions with respect to excipients.
Patient's Risks Associated with Bioinequivalence
Aciclovir has a broad therapeutic index. Oral administration of aciclovir is usually well tolerated, and oral overdosing does not provoke serious adverse effects. Oral aciclovir has no lifethreatening indication, and its therapeutic range seems wide enough to open the possibility for a biowaiver.
CONCLUSION
Aciclovir cannot unequivocally be classified to the BCS because different countries have different highest tablet strengths on their markets, which would lead to different BCS classifications in different countries. But the BCS classification of an API is not a purpose in itself, the relevant question being: is a biowaiver scientifically justified and if justified, which restrictions have to be formulated?
Up to now, the FDA 3 and the EMEA 4 do not accept biowaivers for BCS Class III and BCS Class IV APIs, so acyclovir would obviously be excluded from consideration for a biowaiver in these jurisdictions at the present time. However, the recently revised WHO guidance 2 extended the possibility of a biowaiver approval to BCS Class III APIs under certain conditions.
The risk of an acyclovir drug product being bioinequivalent appears to be very low, provided it contains only excipients present in IR aciclovir solid oral drug products approved in ICH or associated countries, for instance those presented in Table 2 of this article, and meets the biowaiver dissolution criteria. Also, the patient risks associated with a bioinequivalence inadvertently not detected by application of in vitro BE test can be deemed acceptable.
The preponderance of evidence indicates that a biowaiver for IR aciclovir solid oral drug products with strengths up to 800 mg is justified, if: (a) the test product contains only excipients present in aciclovir solid oral drug products approved in ICH or associated countries, for instance as presented in Table 2 of this article, and (b) the comparator and the test product both are very rapidly dissolving, that is, dissolve 85% in 15 min or less, using a basket apparatus at 100 rpm or paddle apparatus at 50 rpm, in a volume of 900 mL or less, in pH 1.2, pH 4.5, and pH 6.8 buffers.
